{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"0.720","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"4,124,080,000","primaryexch":"香港交易所","ric":"2181.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"K","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BHRH2D9","am":"177.76","iv":"","ew_strike":"","as":"0.730","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"0.710","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"2,000","update_time":"2025-09-28 00:06:03.0","lo52":"0.250","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"焦樹閣","underlying_ric":"2181.HK","hi52":"0.940","issuer_name":"邁博藥業有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日15:58","aum_date":"","lo":"0.710","mkt_cap":"2.96","f_aum_hkd":null,"ew_sub_per_to":"","ls":"0.720","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.010","aum":"","issued_shares_class_B":null,"vo":"250.00","secondary_listing_flag":false,"listing_date":"2019年5月31日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"邁博藥業有限公司 - B","nm_s":"邁博藥業—Ｂ","sym":"2181","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"邁博藥業有限公司是一家主要從事癌症及自身免疫性疾病的單抗藥物的研究、開發及生產的投資控股公司。該公司的主要產品包括CMAB009恩立妥（西妥昔單抗β注射液）、CMAB007奧邁舒（注射用奧馬珠單抗α）、CMAB008類停（注射用英夫利西單抗）等產品。該公司的產品主要應用於結直腸癌、哮喘、蕁麻疹、類風濕關節炎、成人潰瘍性結腸炎等疾病。該公司还從事知識產權轉讓。該公司主要在國內市場開展業務。","op":"0.710","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東83號<br/>鴻翔中心<br/>18樓A室","pc":"-1.37","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"0.730","isin":"KYG5780F1046","moneyness":""}},"qid":"1759074962627"}
